Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
FEMALE
NCT07359703

A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle (Aurora-Blasto)

Led by University Hospital, Ghent · Updated on 2026-01-22

1028

Participants Needed

1

Research Sites

189 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Ghent

Lead Sponsor

F

Fertiga, Belgium

Collaborating Sponsor

AI-Summary

What this Trial Is About

In current treatments for In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), the creation of multiple embryos is a common practice. The decision to transfer an embryo is traditionally based on the morphological assessment by an embryologist, which, due to its nature, must be considered subjective. In certain regions, invasive embryo biopsy techniques, such as Preimplantation Genetic Testing for Aneuploidy (PGT-A), are used to detect chromosomal abnormalities and support decision-making regarding embryo transfer. However, there is a medical need to improve the outcomes of IVF/ICSI cycles through non-invasive and objective methods. As an academic center, our goal is to investigate promising innovative methods that, if successful, can be integrated into standard care. The aim of the Aurora blastocyst study is to evaluate the effectiveness of the Aurora test in selecting five-day-old embryos for fresh or frozen embryo transfer. Additionally, the study assesses whether the use of the Aurora test results in an increase in clinical pregnancy rates and live birth rates. The Aurora test is a non-invasive test for evaluating oocyte competence and subsequently the embryo obtained in an ICSI cycle (In Vitro Fertilization). This test is performed on cumulus cells (CC) surrounding the oocyte and uses mRNA expression profiles to evaluate the developmental potential of the oocytes. The test has been developed and validated for patients stimulated with human menopausal gonadotropins (HP-hMG), an ovulatory dose of hCG, and a single embryo transfer on day 3. The test will be performed by Fertiga nv, upon receiving patients cumulus cells. At our center, based on earlier research, the standard care involves a single embryo transfer on day 5. In this study, embryo selection based on morphology is compared with embryo selection based on morphology and the Aurora test. Finally, this study aims to evaluate the impact of the Aurora test score on the embryologist's selection decision for transferring a five-day-old embryo for single embryo transfer, by assessing parameters such as pregnancy rates and live birth rates.

CONDITIONS

Official Title

A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle (Aurora-Blasto)

Who Can Participate

Age: 18Years - 40Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undergoing ICSI treatment, aged 18 to 40 years at signing the informed consent form
  • Patients stimulated with GnRH antagonist/HP-hMG or GnRH antagonist/recFSH, scheduled for fresh or frozen/thawed single embryo transfer on day 5 with hCG, dual trigger, or GnRH agonist trigger
  • Patients undergoing their first to fourth ICSI cycle
  • Women with body mass index (BMI) between 17 and 35
  • Women with regular menstrual cycles between 24 and 35 days
  • Non-smokers or mild smokers (<10 cigarettes per day)
  • AMH 1.1 ng/ml or higher, excluding poor responders according to Bologna criteria
  • Patients using fresh ejaculated semen or frozen donor semen
Not Eligible

You will not qualify if you...

  • Patients with fewer than 8 follicles (≥12mm) on the last ultrasound before oocyte retrieval
  • Women with less than 50% mature oocytes (MII) in a previous cycle
  • Women with severe endometriosis (≥ stage III AFS classification) in the ovaries not surgically treated
  • Patients scheduled for preimplantation genetic diagnosis (PGD) or preimplantation genetic testing for aneuploidy (PGT-A)
  • Couples where the male partner has extremely low sperm count, such as severe oligo-astheno-teratozoospermia (OAT) below 100,000/ml or requiring TESE

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ghent University Hospital

Ghent, Belgium

Actively Recruiting

Loading map...

Research Team

D

Dominic Stoop

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here